Drugs / Liposome bupivacaine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03106545 | Jan → Jun 2017 | — | Catherine Vandepitte, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT03106519 | Jan → Jun 2017 | palmar fibromatosis | Catherine Vandepitte, M.D. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01977339 | May 2015 → Jul 2016 | — | St. Luke's-Roosevelt Hospital Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02274870 | Nov 2014 → Dec 2016 | — | Northwell Health | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06701539 | Dec 2024 → Jun 2025 overdue | — | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposome bupivacaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06701539 ↗ |
| Route | Other | “Single injection femoral nerve block” NCT01977339 ↗ |